Effects of Ublituximab on Motor Functions in Multiple Sclerosis (NCT06629428)
Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People With Relapsing Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.
Who can join: Review the eligibility criteria below.
Location: Georgia State University — Atlanta, Georgia
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Georgia State University — Atlanta, Georgia
- Atlanta Neuroscience Institute — Atlanta, Georgia
📞 Contact the Study Coordinator
Phone: (404) 351-0205
Email: mmitchell@atlneuroinstitute.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis (MS) - Relapsing-remitting
- A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS — Cleveland, Ohio
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis — Baltimore, Maryland
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. — St Louis, Missouri
- Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study — Gainesville, Florida
Explore by condition: All Multiple Sclerosis (MS) - Relapsing-remitting clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.